Table 3.
Clinical features of participants in the gout analysis
| Percentage with data | All (n = 2,578) | Controls (1,368) | Cases (1,210) | P | |
|---|---|---|---|---|---|
| Age, years | 100 | 52.1 (16.4) | 47.0 (16.5) | 57.8 (14.4) | 4.9 × 10−66* |
| Male sex, n (%) | 100 | 1739 (67.5) | 740 (54.1) | 999 (82.6) | <1.0 × 10−5** |
| NZ East Polynesian dataset, n (%) | 100 | 901 (35.0) | 583 (42.6) | 319 (26.4) | <1.0 × 10−5** |
| NZ West Polynesian dataset, n (%) | 100 | 597 (23.2) | 271 (19.8) | 326 (26.9) | |
| NZ Mixed East/West Polynesian dataset, n (%) | 100 | 92 (3.6) | 64 (4.7) | 28 (2.3) | |
| NZ Caucasian dataset, n (%) | 100 | 987 (38.3) | 450 (32.9) | 537 (44.4) | |
| Serum urate at the time of recruitment, mmol/L | 86.5 | 0.39 (0.11) | 0.37 (0.10) | 0.43 (0.11) | 5.9 × 10−37* |
| Triglycerides, mmol/L | 86.9 | 2.14 (1.4) | 1.93 (1.18) | 2.39 (1.60) | 2.3 × 10−14* |
| Body mass index, kg/m2 | 100 | 32.4 (7.6) | 31.3 (7.5) | 33.6 (7.6) | 2.6 × 10−15* |
| Fruit intake, pieces/day | 98.9 | 2.9 (4.6) | 2.8 (4.2) | 3.0 (5.0) | 0.27* |
| Kidney disease, n (%) | 98.0 | 295 (11.7) | 57 (4.3) | 238 (20.1) | <1.0 × 10−5** |
| Hypertension, n (%) | 98.3 | 975 (38.5) | 309 (23.0) | 666 (55.9) | <1.0 × 10−5** |
Unless specified, data are presented as mean (SD)
NZ New Zealand
*Two-sample t test with unequal variances
**Chi-square test